Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sofosbuvir in preparation of medicines for preventing and treating coronavirus

A coronavirus and drug technology, applied in the direction of antiviral agents, drug combinations, pharmaceutical formulations, etc., can solve problems such as the in vivo efficacy is still under observation, and there are no antiviral drugs and vaccines.

Inactive Publication Date: 2020-07-31
SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there is no definite and effective antiviral drug and vaccine
From the analysis of the in vitro antiviral activity data of these drugs, the antiviral IC of most drugs 50 It is between low micromolar and medium micromolar, and the efficacy in vivo is still under observation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sofosbuvir in preparation of medicines for preventing and treating coronavirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Virus Amplification

[0031] African green monkey kidney cells (VeroE6) were divided into 3×10 5Each well was inoculated into a 96-well plate, placed in minimum Eagle’s medium (MEM; GibcoInvitrogen) containing 10% fetal bovine serum (FBS; GibcoInvitrogen) at 37°C, 5% CO 2 Cultivate until the monolayer grows. Inoculate a 100-fold dilution of the clinical isolates of the novel coronavirus pneumonia into a 96-well plate full of monolayer cells, and place at 37°C, 5% CO 2 Culture for two days (including the normal control group).

[0032] Two days later, the lesion degree reached more than 75%. Put it in a -80°C ultra-low temperature refrigerator, freeze and thaw once repeatedly, collect the virus liquid amplified by the cells, centrifuge at 3000r / min for 30 minutes, remove the sediment, put it in a small tube and put it in a -80°C ultra-low temperature freezer Long-term preservation.

Embodiment 2

[0033] Embodiment 2 sofosbuvir drug toxicity evaluation

[0034] After the sofosbuvir powder is dissolved in DMSO, add culture medium to dilute to 20mg / mL, the final concentration of DMSO is 1%, filter through a 0.22μm filter membrane and store at 4°C; after filtering, store at 4°C. Press about 2.5×10 per hole 4 Cells were inoculated into 96-well plates. After 24-48 hours, when the cells had grown into a monolayer, the culture medium was discarded, and 100 μL / well of drugs of different dilutions were added, and 100 μL / well of MEM was added to the control wells of normal cells, and kept at 37°C in 5% CO. 2 Continue culturing for 2 to 5 days, add 20 μL of CCK8 solution (5 mg / mL) to each well, and place at 37°C in 5% CO 2 Continue to incubate for 4 hours in the incubator. Discard the culture supernatant, add 100 μL dimethyl sulfoxide (DMSO) to each well, and shake at low speed for 10 minutes to fully dissolve the crystals. Select a wavelength of 490nm, and measure the light ab...

Embodiment 3

[0035] Example 3 Sofosbuvir anti-new coronary pneumonia novel coronavirus efficacy evaluation

[0036] To evaluate the antiviral efficacy of the drug, VeroE6 cells were grown at a density of 5×10 4 Cells / well were cultured overnight in a 48-well cell culture dish. Add virus (MOI 0.05) to infect for 2 hours. Then add 2-fold gradient dilution of the drug, each concentration set 4 duplicate wells, with 200 μM as the initial concentration of the drug, at 34 ° C, 5% CO 2 Incubate for 2 days in the incubator. Record the cytopathic effect (Cytopathogenic Effect, CPE. The occurrence of CPE in the cells is recorded according to the 6th grade standard. After recording the CPE, stain with the CCK8 method to determine the OD value. Use the Reed-Muench method to calculate the half effective concentration of the drug (EC 50 ) was 1.12 μM. It can be seen from the experimental results that the antiviral half effective concentration of sodium foscarnet is low and the antiviral effect is go...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of sofosbuvir in preparation of medicines for preventing and treating coronavirus, and particularly discloses an application of sofosbuvir or a pharmaceuticallyacceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof in preparation of medicines for preventing and / or treating diseases caused by coronavirus. The coronaviruses are novel coronaviruses SARS-Cov-2, SARS-CoV, HCoV 229E, NL63, OC43, HKU1 and MERS-CoV. The half effective concentration of sofosbuvir on novel coronavirus of Corona Virus Disease 2019 is 1.12 [mu]M, the toxicity is low, and a good treatment window is provided.

Description

technical field [0001] The invention belongs to the field of antiviral drugs, in particular to the application of Sofosbuvir in the preparation of anti-coronavirus drugs for prevention and treatment. Background technique [0002] New Coronary Pneumonia (COVID-19) is an infectious disease caused by a novel coronavirus (SARS-Cov-2) infecting the human body. Its symptoms mainly include fever, fatigue, dry cough, dyspnea, and renal failure [The Lancet, 2020, 395(10223): 507-513; The Lancet, 2020, 395(10223): 497-506]. Coronavirus belongs to Coronaviridae (Coronavirus) in systematic classification. Viruses of the genus Coronavirus are positive-strand single-stranded RNA viruses with an envelope (envelope), with a diameter of about 80-120nm. Its genetic material is the largest among all RNA viruses, and generally only infects humans, mice, pigs, cats, and dogs. , Avian vertebrates. Coronaviruses were first isolated from chickens in 1937. Coronavirus particles are irregular in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7072A61K45/06A61P31/14A61P11/00
CPCA61K31/7072A61K45/06A61P11/00A61P31/14A61K2300/00
Inventor 袁曙光邹荣峰罗木鹏陈显翀崔文强赵金存孙静
Owner SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com